An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00771199|
Recruitment Status : Completed
First Posted : October 13, 2008
Last Update Posted : September 17, 2014
|Condition or disease||Intervention/treatment||Phase|
|Cancer, Pain||Drug: Transdermal Therapeutic System (TTS)-Fentanyl||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Multicenter Study to Evaluate the Safety/Tolerability and Clinical Utility of Low-dose TTS-Fentanyl D-TRANS in Taiwan Patients With Cancer Pain|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||November 2008|
|Actual Study Completion Date :||November 2008|
|Experimental: Transdermal Therapeutic System (TTS)-Fentanyl||
Drug: Transdermal Therapeutic System (TTS)-Fentanyl
Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
- Percentage of Participants Dropped From Study due to Adverse Events [ Time Frame: Day 0 up to Day 28 ]An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical product. An adverse event does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. Percentage of participants who will be prematurely withdrawn from the study due to any adverse events will be reported.
- Brief Pain Inventory (BPI) Score (Question 6) [ Time Frame: Day 0, Day 7, Day 14 and Day 28 ]The BPI question number 6 describes pain severity, will be measured by the daily pain diary on numeric rating scale (NRS), ranging from 1 to 10; where 0 signifies no pain and 10 signifies extreme pain.
- BPI Score (Question 9) - Quality of Life (QOL) [ Time Frame: Day 0, Day 7, Day 14 and Day 28 ]Participant's quality of life (QOL) will be assessed by BPI question number 9 (items 9a to 9g), which describes "how during the past 24 hours pain has interfered with participants general activity, mood, walking ability, normal work, relation with other people, sleep, enjoyment of life". Each item will be measured on NRS, ranges from 1 to 10 where 0 signifies does not interfere and 10 signifies completely interferes. Total score is the average of scores of all items and ranges from 0 to 10, where higher scores signifies higher pain/interference.
- Average Daily Dose and Final Dose of Transdermal Therapeutic System (TTS)-fentanyl [ Time Frame: Day 0 up to Day 28 ]The TTS-fentanyl dosage is only increased in consultation with the treating physician and according to the participant's analgesic requirements, with the intention of maintaining his/ her pain score at 2 or less on the BPI question 6.
- Investigator's Global Assessment Scale Score [ Time Frame: Day 0 and Day 28 ]Investigator will complete a global assessment of the participants treatment with respect to pain control using 4-point scale, where 1 signifies poor, 2 signifies fair, 3 signifies good, 4 signifies very good.
- Percentage of Participants With Treatment Satisfaction [ Time Frame: Day 0 and Day 28 ]Participants will rate their assessment of treatment satisfaction, using 4-point scale where 1 signifies poor, 2 signifies fair, 3 signifies good and 4 signifies very good.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00771199
|Study Director:||Janssen-Cilag Ltd Clinical Trial||Janssen-Cilag Ltd.|